Prova Education Faculty

Public Profile

Christopher P. Cannon, MD
Christopher P. Cannon, MD
  • Education Director, Cardiovascular Innovation
  • Preventive Cardio Section, Brigham & Women’s Hosp.
  • Professor of Medicine, Harvard Medical School
  • Boston, MA

Senior Investigator, TIMI Study Group

Cardiovascular Division, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School
Editor-in-Chief www.Cardiosource.com, American College of Cardiology

Dr. Cannon is an Associate Professor of Medicine at Harvard Medical School and an Associate Physician in the Cardiovascular Division at Brigham and Women's Hospital in Boston. He is a senior investigator of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as TACTICS-TIMI 18, PROVE IT-TIMI 22, CLARITY-TIMI 28.

He earned his medical degree from Columbia University College of Physicians and Surgeons in New York, and after completing his residency in internal medicine at Columbia Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women's Hospital.

In addition to being a frequent lecturer, Dr. Cannon has published more than 500 original articles, reviews, editorials, book chapters, and electronic publications in the field of acute coronary syndromes. His research is published in journals including Circulation, Journal of the American College of Cardiology (ACC), Lancet, Journal of the American Medical Association, and the New England Journal of Medicine. He is Editor-in-Chief of the journal Critical Pathways in Cardiology and a 35-book series Contemporary Cardiology.  He is editor or author of 7 books.  He is the Editor-in-Chief of the American College of Cardiology's website Cardiosource (www.cardiosource.com).

Dr. Cannon has received numerous awards including the Alfred Steiner Research Award, Upjohn Achievement in Research Award, and Robert F. Loeb Award for Excellence in Clinical Medicine. He is a fellow of the American Heart Association (AHA), and the ACC. He serves as Chairman of the AHA's Get With the Guidelines Science Subcommittee, and of the ACC's ACTION registry Steering Committee.  He is the principal investigator of ongoing trials such as IMPROVE IT, which is evaluating the benefit of lowering of LDL cholesterol well below 70 mg/dl with ezetimibe plus simvastatin as compared simvastatin alone.

Register

We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free